Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters

Drug Metabolism and Disposition

Volumn 28, Issue 11, 2000, Pages 1335-1342

  Billecke, S ^a   Draganov, D ^a,b   Counsell, R ^a   Stetson, P ^a,c   Watson, C ^a,d   Hsu, C ^a   La Du, Bert N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MILITARY MEDICAL ACADEMY   (Bulgaria)

^c WIL RESEARCH LABORATORIES   (United States)

^d Esperion Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC CARBOXYLIC ACID; ARYLDIALKYLPHOSPHATASE; CARBONIC ACID DERIVATIVE; COMPACTIN; ESTER; GAMMA BUTYROLACTONE; HOMOCYSTEINE THIOLACTONE; ISOENZYME; LACTAM; LACTONE; MEVALONOLACTONE; MEVINOLIN; NEUROTOXIN; ORGANOPHOSPHATE INSECTICIDE; SIMVASTATIN; SPIRONOLACTONE; THIOLACTONE;

ARTICLE; CATALYSIS; DRUG HYDROLYSIS; DRUG STRUCTURE; ENANTIOMER; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; PRIORITY JOURNAL; STEREOSPECIFICITY;

ARYLDIALKYLPHOSPHATASE; CARBONATES; ESTERASES; ESTERS; HUMANS; HYDROLYSIS; ISOENZYMES; LACTONES;

EID: 0033783020     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Serum esterases I
2. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
3. On the specificity of arylesterase
4. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R
5. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase
6. Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase: An ideal plasma inactivation mechanism
7. Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate
8. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
9. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
10. Further evidence for the concept of bovine plasma arylesterase as a lipoprotein
11. Rabbit serum paraoxonase 3 (PON3) is an HDL-associated lactonase and protects LDL against oxidation
12. The human serum paraoxonase/arylesterase polymorphism
13. A new and rapid colorimetric determination of acetylcholinesterase activity
14. Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of gamma-lactones. I. Tissue localization, stoichiometry, specificity, distinction from esterase
15. Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of γ-lactones. II. Metal ion effects, kinetics, and equilibria
16. Purification of human serum paraoxonase/arylesterase: Evidence for one esterase catalyzing both activities
17. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study
18. The molecular basis of the human serum paraoxonase activity polymorphism
19. Calcium-dependent human serum homocysteine thiolactone hydrolase: A protective mechanism against protein N-homocysteinylation
20. Evaluation of serum-lipid-related cardiovascular risk factors in Alzheimer's disease
21. Improved specific assay for serum arylesterase using a water soluble substrate
22. Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase
23. Lactone-ring-cleaving enzyme: Genetic analysis, novel RNA editing, and evolutionary implications
24. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease
25. Comparison of purified human and rabbit serum paraoxonases
26. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity
27. Homocysteine: Cholesterol of the 90s?
28. The separation of sheep and human serum 'A'-esterase activity into the lipoprotein fraction by ultracentrifugation
29. Homocysteine and vascular disease
30. Genetic polymorphism and interethnic variability of plasma paraoxonase activity
31. The human serum paraoxonase/arylesterase gone (PON1) is one member of a multigene family
32. Determination of paraoxonase (PON1) status requires more than genotyping
33. Preliminary report on the metabolism of γ-butyrolactone and γ-hydroxybutyric acid
34. Dependence of rat serum lactonase upon calcium
35. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
36. Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis: Results of the Austrian Stroke Prevention Study
37. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk actor for coronary artery disease
38. A pseudo-first-order kinetic approach to measurement of acetylcholine hydrolysis by acetylcholinesterase
39. Characteristics of the genetically determined polymorphic forms of human serum paraoxonase/arylesterase
40. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with high density lipoproteins by binding phospholipids: Apolipoprotein A-1 stabilizes activity
41. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase
42. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
43. A simple assay for serum arylesterase using a specific substrate
44. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4
45. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent
46. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug
47. Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R